Clinical Trial

Grid eXplore Mapping Study

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the trial is to find out if the Grid X Mapping Catheter and EnSite X EP System with EnSite X Software v3.1.1, the devices that are being studied, are safe and effective in treating Chinese patients who have atrial fibrillation. Participants will receive a procedure called catheter mapping and ablation to treat their abnormal heart rhythms and are required to complete 4 follow-up visits at 7 days, 3 months, 6 months and 12 months after the procedure for checkups and tests.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-04-10
notable Primary completion moved earlier: 2027-02-07 -> 2026-11-07 2026-04-10
minor Completion moved earlier: 2028-01-31 -> 2027-10-31 2026-04-10
Trial Details
NCT Number NCT07421076
Lead Sponsor Abbott Medical Devices
Conditions Paroxysmal Atrial Fibrillation (PAF)
Enrollment 200 participants
Start Date 2026-04-02
Primary Completion 2026-11-07 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01